Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anisodamine hydrobromide and heparin for sepsis
NCT05634057Recruiting
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised trial of raceanisodamine and low molecular weight heparin calcium in sepsis (2 arms). Primary endpoint: 28-day mortality. Started Jan 2024; status: recruiting.
02
Drugs
raceanisodaminelow molecular weight heparin calcium
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT05634057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05634057.